MOD-12014 (CTP-GHR Antagonist) Human growth hormone receptor (GHR) antagonists are used to treat acromegaly, a disorder caused by excess human growth hormone. MOD-12014 utilizes our Carboxyl Terminal Peptide (CTP) technology, which is also used in successful phase 3 product somatrogon (hGH-CTP), to extend the half-life of the GHR antagonist.